NIH joins campaign to ease SBA grant restrictions

The National Institutes of Health has thrown its weight behind lobbying efforts aimed at lifting restrictions that block biotech firms from SBA grant money. The SBA was automatically refusing to give grants to firms that are majority-owned by venture capital groups. NIH director Elias A. Zerhouni asked the SBA to drop the restriction for biotech companies, saying it perversely cut out companies whose early research success had attracted significant VC support. The Biotechnology Industry Organization has been actively working to change the rules governing SBA grants.

- read this article from The Washington Post for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.